Compound Library Volume I Phase 3 — TRIUMPH
Retatrutide
Triple-receptor agonist
Triple-Receptor Metabolic Peptide
Retatrutide is an investigational metabolic peptide being studied for its simultaneous activity at GLP-1, GIP, and glucagon receptors. Current research focuses on appetite regulation, energy expenditure, body composition, and metabolic health.
CAS Number
2381089-83-2
CLASS
Triple Agonist
GLP-1 / GIP / GCGR
Developer
Eli Lilly
LY3437943
First Published
NEJM 2023
Jastreboff et al.
A New Generation of Metabolic Research
Retatrutide is a next-generation research peptide developed to target three key metabolic receptor pathways simultaneously: GLP-1, GIP, and glucagon (GCGR). This triple-receptor mechanism has made retatrutide one of the most widely studied compounds in modern obesity, weight management, and metabolic research.
Previous metabolic peptides focused on one or two receptor pathways. Semaglutide primarily activates GLP-1 receptors, while tirzepatide combines GLP-1 and GIP activity. Retatrutide expands on these approaches by incorporating glucagon receptor activation, creating a unique pharmacological profile that continues to attract significant scientific attention.
Clinical research has demonstrated substantial effects across multiple metabolic endpoints, leading to increased interest in retatrutide within obesity research, type 2 diabetes research, metabolic health studies, and next-generation peptide development. As a result, retatrutide has become one of the most discussed and actively researched metabolic peptides in current scientific literature.
Three Pathways, One Research Peptide
Retatrutide is distinguished by its simultaneous activity across three key metabolic receptor systems: GLP-1, GIP, and glucagon (GCGR). Each receptor contributes a unique mechanism within metabolic research, and together they form the triple-receptor profile that has made retatrutide one of the most studied peptides in obesity, weight management, and metabolic health research.
GLP-1 Receptor
Shared with Semaglutide and Tirzepatide
GLP-1 receptor activation is associated with appetite regulation, delayed gastric emptying, and glucose-dependent insulin secretion. This pathway forms the foundation of many modern metabolic and weight management research compounds.
GIP Receptor
Shared with Tirzepatide
GIP receptor activity provides an additional incretin pathway involved in insulin sensitivity, energy balance, and metabolic regulation. The combination of GLP-1 and GIP receptor activity helped establish the next generation of metabolic peptide research
Glucagon Receptor (GCGR)
Unique to Retatrutide
Glucagon receptor activation is the distinguishing feature of retatrutide. Researchers believe this pathway may contribute to increased energy expenditure and broader metabolic effects, creating the triple-receptor profile that separates retatrutide from earlier GLP-1 and dual-agonist compounds.
THE DIFFERENTIATOR
The glucagon pathway is what sets retatrutide apart from previous metabolic peptides.
While GLP-1 and GIP receptor activity are shared with earlier compounds, retatrutide introduces a third pathway through glucagon receptor activation (GCGR). This additional mechanism has become one of the defining features of retatrutide research and is a major reason the peptide has attracted significant attention within obesity, metabolic health, and weight management studies.
Published research suggests that combining GLP-1, GIP, and glucagon receptor activity may produce broader metabolic effects than earlier generations of incretin-based therapies, making retatrutide one of the most closely monitored compounds in current metabolic research.
-TRIAL DATA
Phase 2 Clinical Research Results
A randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluated retatrutide across multiple dose groups over a 48-week period. The study enrolled adults with obesity and assessed changes in body weight, metabolic markers, and overall treatment response.
24.2%
Mean Body Weight Reduction 12mg dose • 48 weeks
The highest-dose retatrutide group achieved a mean body weight reduction of 24.2% after 48 weeks, making it one of the most significant weight-loss outcomes reported in metabolic peptide research at the time of publication.
In the same study:
100% of participants achieved at least 5% weight reduction
83% achieved at least 15% weight reduction
26% achieved 30% or greater weight reduction.
Source: New England Journal of Medicine (NEJM), 2023
| Dose Group | Mean Weight Reduction | ≥5% Loss | ≥15% Loss | ≥25% Loss |
|---|---|---|---|---|
| Placebo | -2.1% | 27% | 2% | 0% |
| 1mg | -7.2% | 63% | 12% | 0% |
| 4mg | -12.9% | 88% | 38% | 9% |
| 8mg | -17.3% | 93% | 63% | 24% |
| 12mg | -24.2% | 100% | 83% | 48% |
-COMPARATIVE RESEARCH
Three generations of metabolic peptide research.
Retatrutide has emerged as one of the most researched metabolic peptides in Colombia and worldwide. Following earlier compounds such as Semaglutide and Tirzepatide, Retatrutide expanded receptor coverage through simultaneous GLP-1, GIP, and glucagon receptor activity. This next-generation approach has generated significant interest within obesity, weight management, and metabolic research.
Generation I
Semaglutide
GLP-1 only
Peak Weight Loss
14.9%
STEP 1 trial · 68 weeks
Receptor Coverage
Single — GLP-1
FDA Status
Approved (Wegovy, 2021)
FIRST PUBLISHED
Wilding et al., NEJM 2021
Generation II
Tirzepatide
GLP-1 + GIP
Peak Weight Loss
22.5%
SURMOUNT-1 trial · 72 weeks
Receptor Coverage
Dual — GLP-1, GIP
FDA Status
Approved (Zepbound, 2023)
First Published
Jastreboff et al., NEJM 2022
Generation III
Retatrutide
GLP-1 + GIP + GCGR
Peak Weight Loss
24.2%
Phase 2 · 48 weeks (highest dose)
Receptor Coverage
Triple — GLP-1, GIP, GCGR
FDA Status
Phase 3 (TRIUMPH program)
First Published
Jastreboff et al., NEJM 2023
-SELECTED LITERATURE
Key Retatrutide research and clinical publications.
Key Retatrutide research and clinical publications.
Retatrutide has rapidly become one of the most discussed compounds in metabolic peptide research. The publications below highlight the development of Retatrutide, its receptor pharmacology, and the clinical outcomes that have established it as a significant area of interest within obesity, metabolic health, and GLP-1 research.
I. PHASE 2 OBESITY TRIAL
Triple-Hormone Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Published in the New England Journal of Medicine in 2023, this study reported substantial reductions in body weight across multiple dose groups and helped establish Retatrutide as one of the most closely followed compounds in obesity research.
II. NAFLD SUB-STUDY
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
This publication explored the impact of Retatrutide on liver fat content and metabolic markers, contributing to growing interest in the compound’s broader metabolic research applications.
III. PHASE 1 PHARMACOLOGY
First-In-Human Evaluation of LY3437943
Early pharmacokinetic and safety research examining the triple-receptor mechanism that combines GLP-1, GIP, and glucagon receptor activity within a single molecule.
IV. TYPE 2 DIABETES RESEARCH
Retatrutide in Type 2 Diabetes Research
Phase 2 investigations assessing glycaemic outcomes, metabolic markers, and receptor-mediated effects in subjects with type 2 diabetes.
V. TRIUMPH PROGRAMME
TRIUMPH Clinical Development Programme
A series of ongoing Phase 3 studies designed to further evaluate the clinical potential of Retatrutide across obesity and metabolic health research populations.
-AVAILABLE FROM BOGOTÁ PEPTIDES
Retatrutide, available throughout Colombia.
Bogotá Peptides supplies Retatrutide as a premium research peptide for laboratory and analytical research purposes. Each batch is sourced from established manufacturing partners and supported by batch-specific documentation. Fast nationwide delivery is available throughout Colombia, with same-day delivery available in Bogotá and Medellín.
RESEARCH COMPOUND Retatrutide
Vial Strengths
10 / 20 / 30mg
Purity
≥99% HPLC/MS
Dispatch
Bogotá y Medellín
Retatrutide in Colombia
Researchers seeking Retatrutide in Colombia increasingly prioritise transparency, batch-specific documentation, and reliable nationwide delivery. Bogotá Peptides supplies premium research compounds for laboratory and analytical research purposes, with fast shipping available throughout Colombia. Delivery is available to Bogotá, Medellín, Cali, Cartagena, Barranquilla, Bucaramanga, Pereira, and other major cities, supported by batch-specific documentation and a commitment to quality, consistency, and professional service.